Core Viewpoint - The article highlights the innovative strategy of Huajian Medical (01931) in leveraging Web3 technology and real-world asset (RWA) tokenization to revolutionize the liquidity of innovative drug assets, marking a significant shift in the global financial landscape [1][2]. Group 1: Market Dynamics - The RWA market, excluding stablecoins, is projected to reach $245.5 billion by June 2025, with expectations to expand to $16.1 trillion by 2030, representing 10% of global GDP [2]. - The total market capitalization of global stablecoins has reached $263.6 billion, supported by regulatory frameworks such as the U.S. "Genius Act" and Hong Kong's "Stablecoin Regulation" [2]. Group 2: Strategic Initiatives - Huajian Medical is pursuing a dual listing in Hong Kong and the U.S. to enhance financing channels and promote capital synergy [1]. - The company aims to create a "NewCo + RWA" Web3 exchange ecosystem centered around high-tech medical innovation assets, issuing a proprietary stablecoin (IVDD) and applying for a stablecoin license in the U.S. [1][6]. Group 3: Innovative Financing Model - The RWA tokenization allows for the fragmentation and digitalization of physical assets, enabling 24/7 trading and global liquidity, which is particularly beneficial in the medical innovation sector [2][4]. - By tokenizing assets, Huajian Medical can lower investment thresholds, attracting global capital and improving financing efficiency in the innovative drug industry [4][6]. Group 4: Compliance and Regulatory Strategy - Huajian Medical's strategy includes establishing a fully owned subsidiary in New York for stablecoin license applications while participating in Hong Kong's regulatory sandbox for stablecoins [7]. - The company is developing three foundational infrastructures: an RWA tokenization platform, an IVDD stablecoin issuance and clearing system, and a "coin-stock linkage" mechanism with dual listings [7]. Group 5: Capital Market Signals - The company has executed a stock buyback of 141,000 shares at an average price of HKD 3.16 per share, signaling management's confidence in the strategic direction and market outlook [1][8]. - The IVDD stablecoin holders will have preferential rights to subscribe for Huajian Medical's shares, creating a value cycle between crypto capital and traditional equity markets [8].
回购注入战略强心针！华检医疗（01931）“Newco+RWA交易所+稳定币”强势“破圈”